Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)|
|Citation:||Journal of Bone and Mineral Research, 2004; 19(1):147-154|
|Publisher:||Amer Soc Bone & Mineral Res|
|Beiqing Pan, Amanda N Farrugia, Luen Bik To, David M Findlay, Jonathan Green, Kevin Lynch, Andrew CW Zannettino|
|Abstract:||Bisphosphonates are used to prevent osteoclast-mediated bone loss. Zoledronic acid inhibits osteoclast maturation indirectly by increasing OPG protein secretion and decreasing transmembrane RANKL expression in human osteoblasts. The decreased transmembrane RANKL expression seems to be related to the upregulation of the RANKL sheddase, TACE.|
|Keywords:||Cells, Cultured; Osteoblasts; Humans; Hydroxamic Acids; Diphosphonates; Imidazoles; Metalloendopeptidases; Carrier Proteins; Membrane Glycoproteins; Receptors, Tumor Necrosis Factor; Blotting, Western; Flow Cytometry; Immunohistochemistry; Gene Expression; ADAM Proteins; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Osteoprotegerin; ADAM17 Protein|
|Description:||© American Society for Bone and Mineral Research.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.